| 產品名稱 | NCI-H295R [H295R] |
|---|---|
| 商品貨號 | B167201 |
| Organism | Homo sapiens, human |
| Tissue | adrenal gland/cortex |
| Product Format | frozen |
| Morphology | epithelial |
| Culture Properties | adherent |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | Carcinoma |
| Age | 48 years |
| Gender | female |
| Ethnicity | Black |
| Applications | This line has the ability to produce adrenal androgens. |
| Storage Conditions | liquid nitrogen vapor phase |
| Images |  |
| Derivation | NCI-H295R was adapted from the NCI-H295 pluripotent adrenocortical carcinoma cell line (ATCC CRL-10296) established by A.F. Gazdar and associates from a carcinoma of the adrenal cortex. The original cells were adapted to a culture medium which decreased the population doubling time from 5 days to 2 days. While the original cells grew in suspension, the adapted cells were selected to grow in a monolayer. This cell line retains the ability to produce adrenal androgens. It is responsive to angiotensin II and potassium ions. |
| Clinical Data | 48 years Black female |
| Genes Expressed | aldosterone; cortisol; C19 steroids |
| Cellular Products | aldosterone; cortisol; C19 steroids |
| Comments | It is responsive to angiotensin II and potassium ions.
This cell line retains the ability to produce adrenal androgens. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated DMEM:F12 Medium Catalog No. 30-2006. To make the complete growth medium, add the following components to the base medium: 0.00625 mg/ml insulin; 0.00625 mg/ml transferrin; 6.25 ng/ml selenium; 1.25 mg/ml bovine serum albumin; 0.00535 mg/ml linoleic acid; adjust to a final concentration of 2.5% Nu-Serum I. The additives (insulin, transferrin, selenium, BSA and linoleic acid) are available in the form of ITS+ Premix from Corning (Catalog No. 354352). Nu-Serum is also available from Corning (Catalog No. 355100). |
| Subculturing | Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Subculture Ratio: 1:3 to 1:4 Medium Renewal: 2 to 3 times a week.
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 12 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 4th edition, published by Wiley-Liss, N.Y., 2004.
|
| Cryopreservation | Freeze medium: Complete growth medium + extra 7.5% Nu-Serum, 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Atmosphere: air, 95%; carbon dioxide (CO2), 5% |
| STR Profile | Amelogenin: X CSF1PO: 10,12 D13S317: 13 D16S539: 11 D5S818: 12 D7S820: 9,12 THO1: 9.3 TPOX: 8 vWA: 17,18 |
| Name of Depositor | WE Rainey |
| Deposited As | Homo sapiens |
| References | Rainey WE, et al. The NCI-H295 cell line: a pluripotent model for human adrenocortical studies. Mol. Cell. Endocrinol. 100: 45-50, 1994. PubMed: 8056157 Rainey WE, et al. Regulation of human adrenal carcinoma cell (NCI-H295) production of C19 steroids. J. Clin. Endocrinol. Metab. 77: 731-737, 1993. PubMed: 8396576 Gazdar AF, et al. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res. 50: 5488-5496, 1990. PubMed: 2386954 Bird IM, et al. Human NCI-H295 adrenocortical carcinoma cells: a model for angiotensin- II-responsive aldosterone secretion. Endocrinology 133: 1555-1561, 1993. PubMed: 8404594 Rainey WE, et al. Adrenocortical cell lines. Mol. Cell Endocrinol. 228(1-2): 23-38, 2004. PubMed: 15541570 |
| 梅經理 | 17280875617 | 1438578920 |
| 胡經理 | 13345964880 | 2438244627 |
| 周經理 | 17757487661 | 1296385441 |
| 于經理 | 18067160830 | 2088210172 |
| 沈經理 | 19548299266 | 2662369050 |
| 李經理 | 13626845108 | 972239479 |
